The global fluorescent in situ hybridization (FISH) probe market reached a value of US$ 713.2 Million in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 6.1% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Fluorescent in Situ Hybridization (FISH) Probe refers to a sub-atomic cytogenetic technique that uses fluorescent probes to visualize genetic materials. These probes are molecules that absorb light of a specific wavelength and emit light upon binding with a particular DNA/RNA sequence. They are used to identify structural and numerical abnormalities in chromosomes, therapeutic drug monitoring and the identification of rare genetic diseases. Locus specific, Alphoid/centromeric repeat and whole chromosome probes are some of the types of FISH probes that are being commonly used. They exhibit various advantageous properties, such as high sensitivity and accuracy in recognizing targeted sequences, direct application to both metaphase chromosomes and interphase nuclei and accurate visualization of hybrid signals at the single-cell level.
The increasing prevalence of various genetic and chronic disorders is one of the key factors driving the growth of the market. Furthermore, the growing requirements for In Vitro Diagnostics (IVD) testing and targeted therapies across the globe are also boosting the market growth. In comparison to the traditionally used standard cytogenetic (cell gene) tests, FISH tests can identify minute genetic changes that are usually missed under the microscope. These probes are therefore widely used for the diagnosis, prediction of outcomes and clinical management of cancer and genetic disorders. Additionally, various technological advancements, such as the development of FISH probes with higher sensitivity and accuracy, are creating a positive outlook for the market. Other factors, including the improving healthcare infrastructure, especially in the developing countries, along with extensive research and development (R&D) activities in biotechnology, are expected to drive the market further.
Breakup by Type:
Breakup by Probe Type:
Breakup by Technology:
Breakup by Application:
Breakup by End-User:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Abnova Corporation, Agilent Technologies Inc., Biocare Medical LLC, Biosearch Technologies (LGC Ltd.), Creative Biolabs, F. Hoffmann-La Roche Ltd. (Roche Holding AG), Genemed Biotechnologies Inc. (Sakura Finetek USA Inc.), Merck KGaA, Oxford Gene Technology (Sysmex Corporation), PerkinElmer Inc., ThermoFisher Scientific Inc., etc.
|Base Year of the Analysis||2020|
|Segment Coverage||Type, Probe Type, Technology, Application, End-User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abnova Corporation, Agilent Technologies Inc., Biocare Medical LLC, Biosearch Technologies (LGC Ltd.), Creative Biolabs, F. Hoffmann-La Roche Ltd. (Roche Holding AG), Genemed Biotechnologies Inc. (Sakura Finetek USA Inc.), Merck KGaA, Oxford Gene Technology (Sysmex Corporation), PerkinElmer Inc. and ThermoFisher Scientific Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at